ELV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Elevance Health Inc (ELV) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite recent price volatility and technical weakness, the company's strong financial performance, positive congressional trading activity, and long-term growth potential make it a favorable choice.
The technical indicators show a bearish trend with MACD negatively expanding, RSI at 29.189 (neutral zone), and moving averages indicating downward momentum (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level (S1: 324.98), suggesting limited downside risk in the short term.
Strong Q4 financial performance with revenue up 9.47% YoY, net income up 30.86% YoY, and EPS up 36.46% YoY.
Congressional trading data shows heavy buying activity, indicating confidence in the stock.
Management changes aim to streamline operations, potentially improving efficiency and profitability.
Hedge funds are selling the stock, with a 135.25% increase in selling activity over the last quarter.
Analysts have recently lowered price targets and ratings, citing conservative 2026 guidance and margin concerns.
Technical indicators point to a bearish trend, with the stock underperforming key moving averages.
In Q4 2025, Elevance Health reported strong financial results: Revenue increased by 9.47% YoY to $49.75 billion, net income rose by 30.86% YoY to $547 million, and EPS grew by 36.46% YoY to $2.47. These results reflect robust growth and operational efficiency.
Analysts have mixed views on ELV. While some firms like JPMorgan and UBS maintain Buy or Overweight ratings with price targets around $390-$400, others like RBC Capital have downgraded the stock to Sector Perform, citing conservative guidance and margin concerns. The consensus reflects cautious optimism with a focus on long-term growth potential.
